362 related articles for article (PubMed ID: 31903826)
1. Targeting epigenetic regulators in the treatment of T-cell lymphoma.
Ahmed N; Feldman AL
Expert Rev Hematol; 2020 Feb; 13(2):127-139. PubMed ID: 31903826
[No Abstract] [Full Text] [Related]
2. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Lue JK; Amengual JE; O'Connor OA
Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
[TBL] [Abstract][Full Text] [Related]
5. Can we use epigenetics to prime chemoresistant lymphomas?
Amengual JE
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):85-94. PubMed ID: 33275728
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targeting in lymphoma.
Booth S; Collins G
Br J Haematol; 2021 Jan; 192(1):50-61. PubMed ID: 32609383
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.
Zhang Q; Wang S; Chen J; Yu Z
Int J Med Sci; 2019; 16(3):424-442. PubMed ID: 30911277
[TBL] [Abstract][Full Text] [Related]
8. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
9. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
10. The role of epigenetics in malignant pleural mesothelioma.
Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of lymphomas in the era of epigenetics.
Chebly A; Chouery E; Ropio J; Kourie HR; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Blood Rev; 2021 Jul; 48():100782. PubMed ID: 33229141
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
13. Emerging epigenetic-modulating therapies in lymphoma.
Sermer D; Pasqualucci L; Wendel HG; Melnick A; Younes A
Nat Rev Clin Oncol; 2019 Aug; 16(8):494-507. PubMed ID: 30837715
[TBL] [Abstract][Full Text] [Related]
14. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Strauss J; Figg WD
Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
[TBL] [Abstract][Full Text] [Related]
15. Investigational drugs for T-cell lymphoma.
Ghez D; Danu A; Ribrag V
Expert Opin Investig Drugs; 2016; 25(2):171-81. PubMed ID: 26576861
[TBL] [Abstract][Full Text] [Related]
16. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
[TBL] [Abstract][Full Text] [Related]
17. Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Laribi K; Alani M; Truong C; de Materre AB
Recent Pat Anticancer Drug Discov; 2018; 13(3):308-340. PubMed ID: 29769011
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
19. The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).
Ma H; Davarifar A; Amengual JE
Curr Hematol Malig Rep; 2018 Feb; 13(1):13-24. PubMed ID: 29397528
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
